Search

Your search keyword '"Leiter, Lawrence A."' showing total 228 results

Search Constraints

Start Over You searched for: Author "Leiter, Lawrence A." Remove constraint Author: "Leiter, Lawrence A." Publisher american diabetes association Remove constraint Publisher: american diabetes association
228 results on '"Leiter, Lawrence A."'

Search Results

2. Combination of Multiple Low-Risk Lifestyle Behaviors and Incident Type 2 Diabetes: A Systematic Review and Dose-Response Meta-analysis of Prospective Cohort Studies

3. Glycemic Index Versus Wheat Fiber on Arterial Wall Damage in Diabetes: A Randomized Controlled Trial

4. Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58

5. Glycemic Index versus Wheat Fiber on Arterial Wall Damage in Diabetes: a randomized controlled trial

6. Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes– post hoc analyses from the DECLARE-TIMI 58 trial

7. Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

8. Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58

9. Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58

10. Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58.

11. A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes

12. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

13. Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial.

14. Relation of Change or Substitution of Low- and No-Calorie Sweetened Beverages With Cardiometabolic Outcomes: A Systematic Review and Meta-analysis of Prospective Cohort Studies.

15. 788-P: The Cardiovascular and Renal Benefits of Dapagliflozin Are Independent of Baseline HbA1c: Analyses from DECLARE-TIMI 58

16. 95-LB: LixilanONE CAN: Randomized Trial Comparing a Daily vs. Weekly Titration Algorithm for Switching from Basal Insulin to iGlarLixi Fixed-Ratio Combination in People with T2DM in Canada

17. Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: The ACCORD Lipid Trial

18. Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58

19. A Lesson From 2020: Public Health Matters for Both COVID-19 and Diabetes

20. Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care editors' expert forum

21. Effect of fructose on glycemic control in diabetes: a systematic review and meta-analysis of controlled feeding trials

23. 403-P: Impact of Diabetes-Related Factors and Background Antihyperglycemic Therapy on the Efficacy and Safety of Ticagrelor Added to Aspirin: Insights from the THEMIS Trial

24. 185-OR: Efficacy and Safety of Bempedoic Acid in Patients with Diabetes, Prediabetes, and Normoglycemia: Analysis of Pooled Patient-Level Data from Four Phase 3 Clinical Trials

25. 303-OR: Effect of Dapagliflozin on Risk for Fast Decline in EGFR: Analyses from the DECLARE-TIMI 58 Trial

26. 1021-P: HbA1c Levels and Rates of Hypoglycemia with Insulin Degludec U200 and Insulin Glargine U300 Stratified by Renal Function Subgroups: Post Hoc Analysis from the CONCLUDE Trial

27. 1101-P: Cardiorenal Outcomes with Dapagliflozin by Baseline Glucose Lowering Agents: Analyses from DECLARE-TIMI 58

28. Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease

29. Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study

30. Should A1C targets be individualized for all people with diabetes? Arguments for and against

31. Should C-reactive protein be a target of therapy?

32. A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes.

33. Effect of wheat bran on glycemic control and risk factors for cardiovascular disease in type 2 diabetes. (Clinical Care/Education/Nutrition)

34. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. (Clinical Care/Education/Nutrition)

35. Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58.

37. 244-OR: Effects of Dapagliflozin on the Urinary Albumin-to-Creatinine Ratio in Patients with Type 2 Diabetes: A Predefined Analysis from the DECLARE-TIMI 58 Randomised, Placebo-Controlled Trial

38. The Effect of Liquid Meal Replacements on Cardiometabolic Risk Factors in Overweight/Obese Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials

40. Patient age, ethnicity, medical history, and risk factor profile, but not drug insurance coverage, predict successful attainment of glycemic targets: Time 2 Do More Quality Enhancement Research Initiative (T2DM QUERI)

41. Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study.

47. Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum

48. Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial.

49. A Lesson From 2020: Public Health Matters for Both COVID-19 and Diabetes.

50. Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Editors' Expert Forum.

Catalog

Books, media, physical & digital resources